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Abstract
Background: We conducted a retrospective analysis to investigate treatment results and prognostic factors of
pediatric neuroblastoma patients.
Methods: This retrospective study was carried out analyzing the medical records of patients with the pathological
diagnosis of neuroblastoma seen at South Egypt Cancer Institute, Assiut University during the period from January
2001 and January 2010. After induction chemotherapy, response according to international neuoblastoma response
criteria was assessed. Radiotherapy to patients with residual primary tumor was applied. Overall and event free
survival (OAS and EFS) rates were estimated using Graphed prism program. The Log-rank test was used to examine
differences in OAS and EFS rates. Cox-regression multivariate analysis was done to determine the independent
prognostic factors affecting survival rates.
Results: Fifty three cases were analyzed. The median follow-up duration was 32 months and ranged from 2 to 84
months. The 3-year OAS and EFS rates were 39.4% and 29.3% respectively. Poor prognostic factors included age >1
year of age, N-MYC amplification, and high risk group. The majority of patients (68%) presented in high risk group,
where treatment outcome was poor, as only 21% of patients survived for 3 year.
Conclusion: Multivariate analysis confirmed only the association between survival and risk group. However, in
univariate analysis, local radiation therapy resulted in significant survival improvement. Therefore, radiotherapy
should be given to patients with residual tumor evident after induction chemotherapy and surgery. Future
attempts to improve OAS in high risk group patients with aggressive chemotherapy and bone marrow
transplantation should be considered.
Introduction
Neuroblastoma is the third most common malignancy in
childhood and accounts for at least 15 percent of can-
cer-related deaths in children [1]. Despite concerted
clinical and scientific efforts, prognoses of patients with
high-risk neuroblastoma remain poor. About 30 to 35%
of patients with high-risk disease who are older than
1 year survive more than 5 years [2,3].
Children with neuroblastoma exhibit marked variabil-
ity in outcome when the disease is categorized by age,
stage, and biologic characteristics [4,5]. Efforts to
improve the outcome of patients with neuroblastoma
have focused on identification of risk groups based on
clinical and biologic variables as well as intensification
of therapy for high-risk cases [6].
Patients and Methods
Study subjects
This retrospective study was carried out analyzing the
medical records of patients with the pathological diagno-
sis of neuroblastoma seen at the in the Pediatric Oncol-
ogy, Clinical pathology and Radiotherapy Departments,
SECI, Assiut University during the period from January
2001 and January 2010. Informed consent was obtained
for all patients and the treatment decision was approved
by institutional review board at our center. Eligible
patients had histologically confirmed, neuroblastoma, and
were previously untreated. For each patient, evaluation
was done by history and examination, routine laboratory
investigations, and imaging studies in the form of CT
scan with contrast for the local disease, and bone scan.
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Bone marrow aspirate and biopsy was done for all
patients. Histopathologic diagnosis was obtained from
presenting mass and for uncertain cases, immunohisto-
chemistry by neuron specific enulase was done. Patients
were staged by international neuroblastoma staging sys-
tem [7]. N-MYC amplification was done for all patients,
using FISH in paraffin-embedded tissue sections.
Treatment Schedule
For patients with stage IVs; nine courses of doxorubicin
(1 mg/kg) and cyclophosphamide (33 mg/kg) regimen
(every 3 weeks), were given. For patients with stage III
and IV disease; treatment included six courses of OPEC
alternating with OJEC chemotherapy [table 1]. After the
third and six courses, patients were evaluated for che-
motherapy response by clinical examination, bone mar-
row aspirate and biopsy, CT scan of the local site and
bone scan according to the initial presentation.
Response according to international neuroblastoma
response criteria [7] was assessed. Radiotherapy was
given to patients with residual primary tumor, and for
patients with cord compression as palliative treatment.
CT planning was done for determination of target
volume and critical structures. The radiation target
volume included 1 cm margin around all sites of resi-
dual disease evident after induction chemotherapy and
surgery. Radiotherapy was delivered using 6-MeV
photon beams and antero-posterior/postero-anterior
fields with customized blocks. A total dose of 24 Gy was
given in 16 fractions [1.5 Gy per fraction]; 5 fractions
per week. For younger children who needed anesthesia
for immobilization, a total dose of 21 Gy was adminis-
tered in hypofractionated schedule; 3 fractions [2.1 Gy
per fraction] per week for 10 fractions. The clinical tar-
get volume had to be covered by the 95% isodose calcu-
lated for the reference point.
After-Therapy Monitoring
After completion of therapy, patients were followed up
regularly every 3 months for 1 year, every 6 months for
the next 2 years, and annually thereafter. Follow-up
examinations included physical examination, and routine
laboratory studies. CT scans, and bone scan were done
according to initial presentation. Assessment for treat-
ment-related organ toxicity was done during treatment
and after completion of therapy during follow up.
Statistical Methods
The study cutoff point was January 2010. Overall survi-
val (OAS) was defined as the interval from enrollment
to the date of death from any cause or to last follow-up.
Event free survival (EFS) was defined as the interval
from enrollment of patients to the date of relapse, pro-
gression, or death from any cause or to the date of last
follow-up. Overall and event free survival rates were
estimated using Graphed prism program. The Log-rank
test was used to examine differences in OAS and EFS
rates. Cox-regression multivariate analysis was done to
determine the independent prognostic factors affecting
survival rates.
Results
Patients’ Characteristics [Table 2]
The median age of patients was 2 years (range: 3
months - 13 years). Twelve patients (22.6%) were under
one year of age, and 41 patients (77.4%) above 1 year
(65%). Thirty five patients were male (66%) and 18 were
females (34%). The majority of patients were ≥1 year of
age (41 patients; 77.4%), males (35 patients; 66%), pre-
sented with stages III & IV (49 patients; 92.5%), and
with suprarenal tumor (46 patients; 86.8%). Low risk
group (n = 4, 7.5%) included patients with stage IVs dis-
ease. Intermediate risk group (n = 13, 24.6%) included
patients of <1 year of age with III disease and non
amplified N-MYC (n = 12) as well as one patient of <1
year of age with stage IV disease and non amplified N-
MYC. High risk group (n = 36, 68%) included one
patient of >1 year of age with stage III and amplified
N-MYC, one patient <1 year of age with stage IV dis-
ease and amplified N-MYC and patients >1 year of age
Table 1 Chemotherapy protocols.
OPEC regimen Dose Route and duration of administration Timing
Vi Vincristine 1.5 mg/m2 i.v. Day 1
Cisplatin 80 mg/m2 i.v. (6 hours infusion) Day 2
Etoposide 200 mg/m2 i.v. (2 hours infusion) Day 4
Cyclophosphamide 600 mg/m2 i.v. (2 hours infusion) Day 1
Alternating every 3 weeks with OJEC regimen
Vincristine 1.5 mg/m2 i.v. Day 1
Carboplatin 500 mg/m2 i.v. (6 hour infusion) Day 1
Etoposide 200 mg/m2 i.v. (2 hours infusion) Day 1
Cyclophosphamide 600 mg/m2 i.v. (2 hours infusion) Day 1
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with stage IV disease (n = 34). Thirty six patients
(67.9%) had BM infiltration, and 14 patients (26.4%) had
positive bone scan. N-MYC amplification was detected
in only 11 patients (20.8%). Adrenalectomy was done in
12 patients, adrenalectomy with nephrectomy in 2
patients, and pelvic mass excision in 2 patients. Radio-
therapy to the site of residual primary tumor was given
in 25 patients (47.2%), while palliative irradiation was
given to 12 patients with painful bone metastases. The
median follow-up from the date of enrollment was 32
months and ranged from 2 to 84 months.
For patients <1 year of age (n = 12)
For patients with stage IVs (n = 4)
After nine courses of doxorubicin and cyclophospha-
mide regimen, these patients achieved CR.
For patients with stage III (n = 6)
After 3 courses of OPEC/OJEC regimen, all 6 patients
achieved PR. After 3 additional chemotherapy courses,
4 patients underwent surgical resection and the other
2 patients were irresectable. All 6 patients had received
local radiotherapy.
For patients with stage IV (n = 2)
These 2 patients achieved PR after 6 courses of OPEC/
OJEC regimen. They underwent surgical resection, but
with residual disease. They had received local radiation
therapy.
For patients ≥1 year of age (n = 41)
For patients with stage III (n = 7)
After 3 courses of OPEC/OJEC regimen, one patient
died during chemotherapy at 2 months follow up, and
6 patients showed mixed response, but were irresectable.
After additional 3 chemotherapy courses, they became
resectable, underwent surgical resection, but with resi-
dual disease and received radiotherapy on residual
tumor.
For patients with stage IV (n = 34)
After 3 courses of OPEC/OJEC regimen, 5 patients lost
follow up, and 9 patients showed rapidly progressive dis-
ease with deteriorated general condition and eventually
died; 2 of them died during chemotherapy and 7 shortly
after it at follow up range of 4-8 months. For these
7 patients palliative radiotherapy was given to sites of
painful bone metastases. Six patients had progressive
disease and 14 showed mixed responses. After additional
3 chemotherapy courses, 6 patients with progressive dis-
ease showed stable disease, but were irresectable and
received local radiotherapy. Four patients of those with
mixed response showed stable disease and surgical
resection was attempted. These 4 patients died in the
early postoperative period (3 months). Ten patients of
those with mixed response showed stable disease, but
were irresectale. Five of these 10 patients showed dete-
riorated general condition, received palliative radiother-
apy to sites of painful bone metastases, and eventually
died (at a follow up range of 9-10 months). The remain-
ing 5 patients were given local radiotherapy.
Survival analysis [Table 3, 4 and Figure 1, 2, 3 and 4]
Three-year OAS and EFS rates were 39.4% and 29.3%
respectively, for all patients. Patients with <1 year of age
showed 3-year OAS and EFS of 80% compared to 28.9%
(p = 0.0005, HR: 0.26, 95% CI: 0.12-0.55) and 16.2% (p =
0.0004, HR: 0.26, 95% CI: 0.13-0.55) respectively, for
older patients. For patients with low, intermediate and
Table 2 Patients’ characteristics.
Variable No %
1. Age at diagnosis:
a) <1 year 12 22.6
b) ≥ 1 year 41 77.4
2. Sex
a) Males 35 18
b) Females 66 34
3. Stage
a) III 13 24.6
b) IV 36 67.9
c) IVS 4 7.5
4. Risk group
a) Low Risk 4 7.5
b) Intermediate Risk 13 24.6
c) High Risk 36 67.9
5. Primary site
a) Adrenal glands 46 86.8
b) Paraspinal 4 7.5
c) Pelvis 2 3.8
d) Mediastinal 1 1.9
6. Metastatic sites
a) No metastasis 13 24.5
b) Bone marrow 18 34
c) Bone marrow and bone 14 26.4
d) Bone marrow and brain 2 3.8
e) Bone marrow and lung 1 1.9
f) Bone marrow, bone and liver 1 1.9
g) Bone marrow, lung and liver 1 1.9
h) Bone 1 1.9
i) Liver 1 1.9
j) Subcutaneous nodules 1 1.9
7. MYCN amplification
a) yes 11 20.8
b) no 42 79.2
8. Local Radiotherapy administration
a) yes 25 47.2
b) no 28 52.8
TOTAL 53 100
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high risk diseases,3-year OAS rates were 100%, 74.6% and
20.7% respectively (p < 0.0001) and 3-year EFS rates were
100%, 74.6% and 6.1% respectively (p < 0.0001). Multi-
variate Cox regression analysis confirmed only the asso-
ciation between risk group and both OAS (p = < 0.0001,
HR: 27.96, 95% CI: 5.59-139.87) and EFS (p = < 0.0001,
HR: 38.08, 95% CI: 6.87-210.84) rates. Patients with
N-MYC amplification showed 3-year OAS and EFS rates
of 8.3% and 0% respectively compared to 49% (p = 0.0027,
HR: 4.58, 95% CI: 1.69 - 12.37) and 37.2% (p < 0.0001, HR:
10.64, 95% CI: 3.47 - 32.63) respectively for those no
MYCN amplification. For patients who were given local
radiotherapy, 3-year OAS was 57.6% compared to 23.4%
for those who were not given RT (p = 0.0078, HR: 0.39,
95% CI: 0.19-0.78) while the 3-year EFS rate was 42.5% for
irradiated patients compared to 19.5% for non irradiated
patients (p = 0.032, HR:0.47; 95%CI; 0.24-0.94).
Acute Toxicity and Late Effects [Table 5]
Therapy was well tolerated; where only two patients
(of high risk group) died from septicemia due to febrile
neutropenia. There was also one patient (of high risk
group) developed chest infection after relapse. Chest X
ray, CT chest and pulmonary functions tests revealed
pulmonary fibrosis and this patient died in relapse. There
is no late toxicity developed during the study period.
Regarding grade III hematological toxicity, leucopenia
occurred in 24 patients (45.3%), and thrombocytopenia in
21 patients (39.6%). Regarding grade III non hematologi-
cal toxicity; infection in 18 patients, increased liver
enzyme in 18 patients (34%), ototoxicity in 7 patients
(13.2%) and increased serum creatinine in 4 patients
(7.6%).
Discussion
Most children with low risk neuroblastoma can be cured
with surgery alone [8]. Most infants with disseminated
disease have favorable outcomes following treatment
with chemotherapy and surgery [4]. In contrast, the
majority of children with high risk disease die from pro-
gressive disease despite intensive multimodality therapy.
Current multimodality protocols for high-risk neuroblas-
toma patients have incorporated radiation to the pri-
mary disease site [9]. It was suggested that radiation to
the primary tumor bed might benefit patients with gross
residual disease at the time of radiation [10], with irra-
diation of active tumor residual instead of initial tumor
extension [11].
In the current study, the median age of patients was
2 years and was confirmed by Papaioannou and
McHugh [12] who stated that the most undifferentiated
Table 3 Univariate analysis of prognostic factors affecting OAS and EFS rates.
P value 3-year EFS P value 3-year OAS factor
1-Age P = 0.0005 P = 0.0004
1 year (12)> 80% HR:0.26,95%CI; 80% HR:0.26,95%CI;
≥1 years (41) 28.9% 0.12-0.55 16.2% 0.12-0.55
2-Sex P = 0.902 P = 0.84
Males (35) 41.4% HR:1.05,95%CI; 30.9% HR: 1.09, 95%CI;
Females (18) 34.7% 0.502-2.184 28.1% 0.52 - 2.24
3-Risk group p < 0.0001 p < 0.0001
Low Risk (4) 100% 100%
Intermediate Risk (13) 74.6% 74.6%
High Risk (36) 20.7% 6.1%
4-Primary site P = 0.059 P = 0.23
a) Adrenal glands (46) 32.7% HR:2.44,95%CI; 27% HR: 1.77, 95%CI;
b)Other sites (7) 71.4% 0.97-6.16 57.1% 0.697 - 4.530
5-MYCN amplification P = 0.0027 P < 0.0001
yes (11) 8.3% HR:4.58; 95%CI; 0 HR:10.64; 95%CI;
no (42) 49% 1.69 - 12.37 37.2% 3.47 - 82.63
6-Local RT administration p = 0.0078 p = 0.032
Yes (25) 57.6% HR:0.39; 95%CI; 42.5% HR:0.47; 95%CI;
No (28) 23.4% 0.19 - 0.78 19.5% 0.24-0.94
Table 4 Results of the multivariate Cox regression
analysis.
Factor Significance HR 95% CI
OAS
Risk group <0.0001 27.96 5.59 - 139.87
PFS
Risk group <0.0001 38.08 6.87 - 210.84
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and aggressive neuroblastoma presents in young chil-
dren with the median age ≤2 years. Compared with the
current study, the reported studies, showed higher inci-
dence of infants (45%) [13] and lower male to female
ratio (1.3: 1) [14] and this may be explained by higher
total number of patients (n = 500 - 594) in their studies.
Most of our patients presented with stage III & IV
(92.5%). In the reported studies, it was found that the
stages most frequently encountered at diagnosis were
stages III and IV [15,16], and that 70% of the cases of
children with NB presented with metastasis at diagnosis
[17]. The distribution of our patients according to risk
stratification (low risk in 7.5% and high risk in 68%) was
different from that of Oberthuer et al. [18] (low risk in
50% and high risk in 40%) who used a gene expression-
based classifier for neuroblastoma patients to reliably
predicts courses of the disease. N-MYC amplification
was detected in only 11 patients (21%) in the present
study. This is lower than that found by Hass-Kogan et
al., (27%) [10] and Schmid et al., (31%) [4], probably due
Figure 1 OAS according to risk group.
Figure 2 EFS according to risk group.
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to higher total number of patients (n = 134 - 539) in the
reported studies [4,10].
The prognosis for neuroblastoma varies because of its
peculiar biologic behavior [19]. The estimated OAS and
EFS rates at 3 years for our patients were 39.4 and
29.3%, respectively. Three year OAS and EFS rates were
significantly better in the 12 infants (80%) compared
with the 41 children ≥1 year of age (29%; P = 0.0005
and 16.2%; P = 0.0004, respectively). This was confirmed
by Evans and D’Angio, [20] who stated that, age younger
than 1 year is a strongly favorable factor by itself. It was
stated that OAS and EFS rates were significantly better
in infants compared with children ≥1 year of age
[21,22]. However, Schmidt et al [23], showed that EFS
was 74% for the 12- to 18-month age group compared
with 31% for those 18 to 24 months of age (P = .008).
The COG stratified patients into low, intermediate, or
high risk categories based on prognostic features.
Figure 3 OAS according to radiotherapy administration.
Figure 4 EFS according to radiotherapy administration.
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Following a meeting in 2005 to review data obtained for
11054 patients treated between 1974 and 2002, age,
stage at diagnosis, and N-MYC status were selected for
initial risk grouping [24]. In the present study, for
patients with low, intermediate and high risk diseases,
3-year OAS rates were 100%, 74.6% and 20.7% respec-
tively (p < 0.0001) and 3-year EFS rates were 100%,
74.6% and 6.1% respectively (p < 0.0001). Multivariate
analysis confirmed only the association between survival
and risk group. In low risk patients,4-year EFS and OAS
rates of 81% ± 4% and 98% ± 1.5%, respectively, were
reported in previous CCG studies following treatment
with surgery alone [8]. Our figures in low risk group
(100%, 3-year OAS and EFS rates) were comparable to
that reported by Bowman et al, [25] where the estimated
3-year OAS rate for patients with hyperdiploid tumors
that lacked N-MYC amplification was 96%. These find-
ings supported the reduction-in-therapy approach that
was tested in the current COG low-risk study. The over-
all objective of the COG low-risk study was to preserve
the excellent survival rate for patients with low-risk NB
by using surgery as the primary treatment approach,
thereby minimizing the risks of acute and long-term
chemotherapy-related morbidity for the majority of
these patients [26].
Survival rates in intermediate risk group (75%, 3-year
OAS and EFS rates) in the present study was also com-
parable to that found in one of the reported study,
where patients showed estimated 3-year EFS and OAS
rates of 85% and 95% respectively [27].
Survival for high-risk children has improved modestly
during the past 20 years, although cure rates remain
low. Survival rates in high risk group (20.7%, 3-year
OAS and 6% EFS rates) in the present study were very
low. In the literatures, these patients had long-term sur-
vival of only 10 to 20 percent with combination che-
motherapy, surgery, and local radiation therapy [1].
However, treatment approaches that used a combination
of induction therapy, myloablative consolidation therapy
with stem cell support, and biologic therapy had
improved 5-year survival rates from less than 15% to
40% [24].
In the present study, patients with N-MYC amplifica-
tion showed statistically significant lower 3-year OAS
and EFS rates (8.3% and 0%, respectively) than OAS
(49%, p = 0.0027) and EFS (37%, p < 0.0001) in patients
with no N-MYC amplification. This was consistent with
reported series [26].
Regarding radiotherapy, outcome analysis focused on
EFS and OAS rather than local control rates, since local
treatment must aim to improve the survival of each
individual patient [19]. The NB97 radiotherapy approach
(36 Gy to residual tissue on the local tumor site) did
compensate the outcome disadvantage of incomplete
response to induction therapy. The authors discussed
that radiotherapy might be able to compensate a sus-
pected disadvantage of residual tumor [11]. Our data
supported this hypothesis, as there were statistically sig-
nificant higher 3-year OAS and EFS rates (57.6% and
42.5%, respectively) in patients who were given local
radiotherapy than OAS (23%, p = 0.0078) and EFS
(19.5%, p = 0.032) in patients with no local radiotherapy.
This was matched with Simon et al., [11] where 3-year
EFS and OAS rates were statistically significant lower if
residual primary tumor was not irradiated than those in
irradiated patients. This was also confirmed by Castle-
berry et al., [28] who used chemotherapy with or with-
out radiotherapy. Overall survival (73% vs 41%) was
better in the group receiving radiation. Therefore, it is
recommended to give local radiotherapy to the residual
primary tumor site [10].
Grade III leucopenia occurred in 24 patients (45.3%),
and thrombocytopenia in 21 patients (39.6%). In the
reported studies, grade 3/4 hematologic toxicity was
more common (66 - 71%) and may be due to longer
duration of induction chemotherapy [4] or more inten-
sive chemotherapy course [27]. Infection was detected in
18 patients (34%) in the current study, which was within
the range (24 - 58%) found in the reported studies
[27,29]. Seven patients (13.2%) developed ototoxicity
and 4 (7.6%) developed renal impairment in the present
study. These figures were comparable to those found in
CCG-3881, where renal and ototoxicity greater than
grade 2 occurred in 3-6% of patients [4,29].
Conclusion
The majority of patients (68%) presented in high risk
group, where treatment outcome was poor. Multivariate
analysis confirmed only the association between survival
and risk group. However, in univariate analysis, there
were statistically significant higher 3-year OAS and
3-year EFS rates in patients who were given local radio-
therapy compared to survival rates in non irradiated
patients. Therefore, radiotherapy should be given to
patients with residual tumor evident after induction che-
motherapy and surgery. Future attempts to improve
Table 5 Treatment toxicity rates.
Toxicity Grade III
No (95% CI)%
Leucopenia 24 45.3 (31.88 - 58.68)
Thrombocytopenia 21 39.6 (26.45 - 52.79)
Infection 18 34 (21.21 - 46.71)
Increased liver enzymes 18 34 (21.21 - 46.71)
Nausea and vomiting 10 18.9 (8.34 - 29.4)
Ototoxicity 7 13.2 (4.09 - 22.33)
Increased serum creatinine 4 7.6 (0.44 - 14.66)
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OAS in high risk group patients with aggressive che-
motherapy and bone marrow transplantation should be
considered.
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